These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 17302885)
1. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility? Maccarrone M; Wang H; Dey SK Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885 [No Abstract] [Full Text] [Related]
2. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Ward SJ; Raffa RB Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141 [No Abstract] [Full Text] [Related]
3. The safety of obesity drugs. Van Gaal LF; Scheen AJ; Formiguera X Expert Opin Drug Saf; 2007 Sep; 6(5):475-6; author reply 477-8. PubMed ID: 17877434 [No Abstract] [Full Text] [Related]
4. End of the line for cannabinoid receptor 1 as an anti-obesity target? Jones D Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439 [TBL] [Abstract][Full Text] [Related]
5. Cannabinoid receptor CB1 antagonists state of the art and challenges. Bifulco M; Santoro A; Laezza C; Malfitano AM Vitam Horm; 2009; 81():159-89. PubMed ID: 19647112 [TBL] [Abstract][Full Text] [Related]
6. [Sleep disorders associated with treatment with rimonabant]. Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208 [No Abstract] [Full Text] [Related]
7. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. Warren KR; Buchanan RW; Feldman S; Conley RR; Linthicum J; Ball MP; Liu F; McMahon RP; Gorelick DA; Huestis MA; Kelly DL J Clin Psychopharmacol; 2013 Feb; 33(1):118-20. PubMed ID: 23277241 [No Abstract] [Full Text] [Related]
9. Rimonabant and progression of atherosclerosis in obese persons. Dora JM; Scheffel RS JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538 [No Abstract] [Full Text] [Related]
10. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? Di Marzo V Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695 [No Abstract] [Full Text] [Related]
11. Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. van Oosten BW; Killestein J; Mathus-Vliegen EM; Polman CH Mult Scler; 2004 Jun; 10(3):330-1. PubMed ID: 15222701 [TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid system as a novel approach for managing obesity. Lillo JL J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530 [TBL] [Abstract][Full Text] [Related]
13. The psychiatric side-effects of rimonabant. Moreira FA; Crippa JA Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688 [TBL] [Abstract][Full Text] [Related]
17. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo. Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422 [No Abstract] [Full Text] [Related]